Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gene Alteration Protects from Artery Disease

January 28, 2011 7:03 am | News | Comments

A team of scientists has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.

TOPICS:

Antibiotic Could Aid Cancer Fight

January 28, 2011 7:01 am | News | Comments

An antibiotic known for immunosuppression could also point the way to the development of new anti-cancer agents, researchers have reported. Tautomycetin targets an enzyme which plays an important role in cell activities such as proliferation and differentiation.

TOPICS:

Tibotec Licenses Rilpivirine to Mylan

January 28, 2011 6:57 am | News | Comments

Mylan Inc. said it acquired a license to make and sell a generic version of a potential HIV drug in sub-Saharan Africa, India, and some developing countries.

TOPICS:
Advertisement

Lilly Income Up 28%

January 28, 2011 6:55 am | by Tom Murphy | News | Comments

Eli Lilly and Co.'s fourth-quarter net income jumped 28 percent on sales from established drugs, but it expects earnings to slide this year as it faces generic competition and health care overhaul costs.

TOPICS:

FDA Approves Mylan Generics

January 28, 2011 6:54 am | News | Comments

Drugmaker Mylan Inc. said the Food and Drug Administration has approved four dose amounts of its generic version of Shionogi Pharma's Sular tablets for treating hypertension.

TOPICS:

FDA Questions GSK on Avodart

January 28, 2011 6:52 am | News | Comments

GlaxoSmithKline Plc. said the Food and Drug Administration is asking the company for more information before approving the drug Avodart for men at risk of getting prostate cancer.

TOPICS:

Down Economy Hits Drugmakers

January 28, 2011 6:51 am | by Linda A. Johnson | News | Comments

Major drugmakers are reporting fourth-quarter earnings ranging from modestly better to bleak, but they're all showing dents from the macroeconomic forces that constrain the industry, now and for the foreseeable future.

TOPICS:

Iniparib Fails Breast Cancer Trial

January 28, 2011 6:49 am | News | Comments

French drugmaker Sanofi-Aventis SA said a clinical trial showed its drug candidate iniparib did not improve survival or slow disease progression in patients with breast cancer.

TOPICS:
Advertisement

Polypropylene Storage Tube

January 27, 2011 7:52 am | Product Releases | Comments

Micronic Europe has announced a new 1.4ml amber polypropylene storage tube that, used in conjunction with a secure screw cap, ensures the integrity of light sensitive biological samples even over long-term storage periods.

TOPICS:

Reagent Trough

January 27, 2011 7:50 am | Product Releases | Comments

Tecan has launched a new 25 ml trough designed to reduce waste of valuable reagents in automated liquid handling applications. These troughs have a conical base design to minimize the inaccessible liquid volume.

TOPICS:

Nanoparticles Speed Wound Healing

January 27, 2011 7:45 am | News | Comments

Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers.

TOPICS:

New Anti-HIV Gene Therapy Developed

January 27, 2011 7:37 am | News | Comments

An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a newly published paper.

TOPICS:

BioFocus Working with Lundbeck

January 27, 2011 7:23 am | News | Comments

BioFocus announced that a subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck’s liquid chemical library collection.

TOPICS:

Cetero Finishes 20,000th Study

January 27, 2011 7:17 am | News | Comments

Cetero Research has conducted its milestone 20,000th early-phase clinical study. This achievement highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology, and generic clients.

TOPICS:

Provectus Completes Liver Cancer Trial

January 27, 2011 7:13 am | News | Comments

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading